In several ataxia treatment studies, frataxin itself has emerged as a key drug target.[44] Combining cryogenic and room‐temperature structures CyaY—the bacterial homolog of frataxin—enhances our drug‐design efforts by revealing dynamic side‐chain rotamers, and key water‐mediated interactions that cryo alone may miss. This evidence concerns the gene FXN and Ataxia.